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Inhibition of Stat3 signaling ameliorates
atrophy of the soleus muscles in mice
lacking the vitamin D receptor
Suchitra D. Gopinath
Abstract
Background: Although skeletal muscle wasting has long been observed as a clinical outcome of impaired vitamin
D signaling, precise molecular mechanisms that mediate the loss of muscle mass in the absence of vitamin D
signaling are less clear. To determine the molecular consequences of vitamin D signaling, we analyzed the role of
signal transducer and activator of transcription 3 (Stat3) signaling, a known contributor to various muscle wasting
pathologies, in skeletal muscles.
Methods: We isolated soleus (slow) and tibialis anterior (fast) muscles from mice lacking the vitamin D receptor
(VDR−/−) and used western blot analysis, quantitative RTPCR, and pharmacological intervention to analyze muscle
atrophy in VDR−/− mice.
Results: We found that slow and fast subsets of muscles of the VDR−/− mice displayed elevated levels of
phosphorylated Stat3 accompanied by an increase in Myostatin expression and signaling. Consequently, we
observed reduced activity of mammalian target of rapamycin (mTOR) signaling components, ribosomal S6 kinase
(p70S6K) and ribosomal S6 protein (rpS6), that regulate protein synthesis and cell size, respectively. Concomitantly,
we observed an increase in atrophy regulators and a block in autophagic gene expression. An examination of the
upstream regulation of Stat3 levels in VDR−/− muscles revealed an increase in IL-6 protein expression in the soleus,
but not in the tibialis anterior muscles. To investigate the involvement of satellite cells (SCs) in atrophy in VDR−/−
mice, we found that there was no significant deficit in SC numbers in VDR−/− muscles compared to the wild type.
Unlike its expression within VDR−/− fibers, Myostatin levels in VDR−/− SCs from bulk muscles were similar to those of
wild type. However, VDR−/− SCs induced to differentiate in culture displayed increased p-Stat3 signaling and
Myostatin expression. Finally, VDR−/− mice injected with a Stat3 inhibitor displayed reduced Myostatin expression
and function and restored active p70S6K and rpS6 levels, resulting in an amelioration of loss of muscle mass in the
soleus muscles.
Conclusions: The loss of muscle mass in slow muscles in the absence of vitamin D signaling is due to elevated
levels of phosphorylated Stat3 that leads to an increase in Myostatin signaling, which in turn decreases protein
synthesis and fiber size through the phosphorylation of p70S6K and rpS6, respectively.
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Background
Vitamin D deficiency has only recently been recognized
as a worldwide problem and has wide-ranging effects
besides skeletal defects [1–3]. Several tissues are indir-
ectly affected by impaired vitamin D signaling due to
perturbations in calcium and phosphate-dependent
signaling processes [4, 5]. In the skeletal muscle, vitamin
D regulation of calcium uptake modulates glucose me-
tabolism and transcriptional upregulation of myocyte-
enhancer factors 2A and 2D [6, 7]. Consequently,
patients with genetic defects in the vitamin D-activating
enzyme, 25-hydroxyvitamin D 1α-hyroxylase, and in het-
erogeneous loss of function mutations in the vitamin D
receptor (VDR) display progressive muscle weakness and
muscle atrophy [8–10]. However, initial evidence for the
direct action of vitamin D on the skeletal muscle came
from studies in chicks demonstrating that there was no
correlation between myopathy as a result of vitamin D
deficiency and phosphate and calcium levels in serum
and that the restoration of calcium levels did not allevi-
ate muscle weakness [11]. These results were further
corroborated in experiments examining abnormalities in
skeletal muscle development in mutant mice lacking
VDR (VDR−/−) that manifested in a manner independent
of changes in serum metabolites [12, 13]. However, sig-
naling pathways that link the aberrations in myogenic
gene expression and the progressive muscle atrophy
observed postnatally in VDR−/− muscles have been unex-
plored. More importantly, recent evidence indicates that
components of the vitamin D signaling cascade are
expressed in human precursor cells and that the VDR in
rodent quadriceps muscle responds to 1α,25(OH)2D3
treatment [14, 15]. Nevertheless, mechanistic studies
that account for the muscle atrophy observed in vitamin
D-deficient individuals are lacking.
The process of muscle wasting is an inherently hetero-
geneous process, with different sets of muscles consist-
ing of distinct fiber types displaying differential
sensitivities to the same stimulus [16–19]. In humans,
vitamin D-deficient patients displayed a greater tendency
toward type IIb fiber (fast twitch) atrophy than type 1
fiber (slow twitch) atrophy [20]. However, in the VDR−/−
mice, muscle fibers are smaller than wild type irrespect-
ive of the fiber type [13]. These differences in the effects
of vitamin D signaling between mice and humans sug-
gest that the effects of VDR deletion are more multifari-
ous than the deficiency of 1α,25(OH)2D3 alone. As such,
since both subsets are impacted by the loss of vitamin D
signaling, the VDR−/− mice offer a model that allows us
to address the consequences of specific signaling path-
ways in promoting muscle wasting in slow and fast sub-
sets of muscles. More importantly, mechanistic insights
in the VDR−/− mouse model provide targets for interven-
tion in cases where supplementation of vitamin D is not
a viable option, such as in the instances of genetic
defects resulting in loss of function mutations in the
vitamin D signaling system.
Persistent signal transducer and activator of transcrip-
tion 3 (Stat3) signaling has been linked to muscle wast-
ing in response to enhanced interleukin-6 (IL-6)
stimulation through Myostatin [21, 22]. In this study, we
examine the role of activated Stat3 signaling in promot-
ing skeletal muscle atrophy observed in VDR−/− mice, in
muscles with a predominance of type 1 fibers (soleus)
and type II fibers (tibialis anterior (TA)). We show that
increased Stat3 signaling is accompanied by an increase
in the expression of Myostatin, a negative regulator of
muscle mass. Consequently, Myostatin signaling through
p-Smad3 reduces phosphorylated ribosomal protein S6
kinase (p-p70S6K) and its substrate, phosphorylated
ribosomal protein S6 (p-rpS6), that represent hallmarks
of mammalian target of rapamycin (mTOR) signaling
[23]. While p70S6K activity is associated with modulat-
ing protein synthesis, rpS6 phosphorylation has been
established as a key determinant of cell proliferation, cell
size, and glucose homeostasis [24, 25]. Finally, to deter-
mine the importance of the Stat3 pathway in mediating
the effects of vitamin D on muscle mass, we address
whether pharmacological inhibition of Stat3 signaling in
vivo can ameliorate the loss of muscle mass observed in
the absence of vitamin D signaling.
Methods
Animals
VDR-null mutant mice were obtained from Jackson
Laboratories (stock no: 006133, B6.129S4-Vdrtm1Mbd lJ;
Bar harbor, ME, USA) and bred at the Small Animal Fa-
cility at the National Institute of Immunology, New
Delhi, India. All mice were fed ad libitum with a
commercially available rodent chow and with tap water
supplemented with 1% calcium, 1% phosphate, and 2%
lactose. Mice were housed in a sterile facility in individu-
ally ventilated cages (IVC). Animal strain maintenance,
post mortem collection of tissues, drug treatments, and
husbandry were carried out according to the guidelines
of and with the approval of the Animal Ethics Commit-
tee at the National Institute of Immunology.
RNA extraction and quantitative RT-PCR
Dissected soleus and TA muscles were snap frozen in
liquid nitrogen and homogenized in TRIzol® Reagent
(1 ml/mg tissue; Thermo Fisher Scientific) to isolate
total muscle RNA as per the manufacturer’s recommen-
dations. Total RNA was quantified with a Nanodrop
8000 Spectrophotometer (Thermo Scientific, Wilming-
ton) and a ratio of 2 for the absorbance of 260 to
280 nm was used to determine the RNA quality. First-
strand cDNA was synthesized from total RNA using the
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First Strand SuperScript Synthesis System with Super-
Script II reverse transcriptase according to the manufac-
turer’s protocols (Invitrogen, Carlsbad, CA). Quantitative
RT-PCR was performed using the Mastercycler® Real-
Plex2 from Eppendorf with Power SYBR® Green PCR
Master Mix (Applied Biosystems). Each sample was
amplified in triplicates using primers specific to Myosta-
tin [22], Foxo3 [26], Murf1 and C/EBP δ [22], LC3b and
Bnip3 [27], and glyceraldehyde 3-phosphate dehydrogen-
ase (Gapdh) [26]. Expression levels were normalized to
Gapdh.
Satellite cell isolation and fluorescence-activated cell
sorting
Satellite cells were isolated from the hind limb muscles
as described earlier [28]. After enzymatic digestion of
the myofibers, mononuclear cells were stained with
Vcam-biotin (clone 429; BD Bioscience), CD31-APC
(clone MEC 13.3; BD Bioscience), CD45-APC (clone 30-
F11; BD Bioscience), and Sca-1-PE-cy7 (clone D7;
eBioscience) [28, 29]. Streptavidin-PE was used to amp-
lify the Vcam signal (BD Bioscience). Cells were sorted
using a BD fluorescence-activated cell sorting (FACS)
ARIA III cell sorter. A post-sort profile was carried out
after every experiment to determine sort purity. Add-
itionally, a small fraction of cells was stained for MyoD
to determine the myogenic status of the sorted cells.
Western blotting and antibodies
Protein extracts from the tibialis anterior and soleus
muscles of wild-type and VDR−/− mice were obtained by
homogenizing muscles in lysis buffer (50 mM Tris-HCl
pH 7.5, 150 mM NaCl, 5 mM EDTA, 1% NP40, 0.5% so-
dium deoxycholate, 0.1% SDS) containing phosphatase
inhibitors (10 mM Na3VO4, 100 mM NaF) and protease
inhibitors (Roche). The proteins were resolved by SDS-
PAGE (8%) and transferred onto nitrocellulose mem-
branes. The membranes were incubated with primary
antibodies followed by incubation with HRP-conjugated
anti-mouse or anti-rabbit secondary antibodies and visu-
alized using Supersignal West Pico Chemiluminescent
Substrate (Thermo Scientific, Rockford, IL, USA). Blots
were probed with antibodies against p-Stat3 (clone # B-
7, cat # sc-8059, Santa Cruz Biotechnology), p-rpS6
(clone # 91B2, cat # 4857), S6 ribosomal protein (clone #
5G10, cat # 2217), p-p70S6 kinase (Thre389, #9205, Cell
Signaling Technology, Beverly, MA), p70S6 kinase
(#9202s, Cell Signaling Technology, Beverly, MA), p-
Stat5 (Clone C11C5, cat # 9359), Stat5 (cat # 9363),
Stat3 (cat # 4904), IL-6 (cat # 12912, Cell Signaling
Technology, Beverly, MA), p-Smad3 (Ser423/425)
(C25A9, #9520, Cell Signaling Technology, Beverly,
MA), slow myosin (NOQ 7.5.4D, cat # M8421, Sigma-
Aldrich), Myogenin (F5D, #ab1835 Abcam), GAPDH,
and β-actin (cat # sc-47724 and # sc-47778, respectively,
Santa Cruz Biotechnology).
Enzyme-linked immunosorbent assay
ELISA plates (Nunc MaxiSorp) were coated overnight at
4 °C with 1 μg of the respective capture antibody or mock
BSA prepared in coating buffer as per the manufacturer’s
instructions. After blocking in the ELISA/ELISPOT dilu-
ent, sera isolated from retro-orbital bleeds and muscle ly-
sates from the soleus and TA muscles from wild-type
(WT) and V mice were incubated for 3 h at 37 °C. Plates
were thoroughly washed and incubated with the respect-
ive biotinylated goat polyclonal anti-mouse antibody
against IL-6, interferon-γ (IFNγ) (cat # 88-7064-88 and
cat # 88-734-88, respectively, eBioscience), and tumor
necrosis-α (TNFα) (cat # 430904, BioLegend). Binding
was detected by peroxidase linked to avidin. Enzyme activ-
ity was measured using TMB.
Drug treatment
Four-and-a-half-week-old VDR−/− male mice that were
paired for comparable weights were injected with
6.25 mg/kg of the Stat3 inhibitor Xlll, C188-9 (Merck,
Millipore, catalog # 573128-10MGCN) in 5% dextrose in
water (5DW), or 5DW alone, intraperitoneally daily for
13 days. Wild-type mice were injected with the Stat3 in-
hibitor or 5DW as corresponding controls. On the 14th
day, mice were euthanized and the soleus and TA mus-
cles were collected and processed for protein and RNA
isolation.
Histological analysis
The soleus muscles harvested from the mice were snap
frozen in liquid nitrogen and prepared for obtaining
8 μm cryosections. Histological analysis was performed
using hematoxylin and eosin (Sigma-Aldrich) staining. A
minimum of 800 fibers were examined in replicates of
three for each group. The circumference of each fiber
was outlined using ImageJ software (v. 1.49).
Statistical analyses
A minimum of five replicates in terms of individual
animals was used per experiment, and data are repre-
sented as mean ± SEM. Student’s unpaired t test with
unequal variance was used to test for statistically signifi-
cant differences between groups using GraphPad Prism
Software (Version 5.0). The p < 0.05 level was considered
significant. For isolation of RNA from SCs, a minimum
of three animals was used and FACS-sorted cells were
pooled for further analysis.
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Results
Activated Stat3 protein (p-Stat3) is increased in VDR−/−
muscles
Previous reports have demonstrated that although the
VDR−/− mice display no defects in growth or difference in
body weight before weaning (3 weeks), the following
period is characterized by a significant reduction in body
weight with a viability of a maximum of 15 weeks (Fig. 1a)
[12]. Additionally, as earlier reported [30], there were no
differences in the quantity of food intake between the
wild-type and VDR−/− mice (3 g ± 0.25/day) at the ages
examined. In terms of activity, previous studies have
reported profound muscular and motor impairments that
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Fig. 1 Reduced weight and elevated p-Stat3 levels displayed by VDR−/− muscles. Graph shows average weights of the whole body of wild-type
(W) and VDR−/− mice (V) at 2, 6, and 8 weeks of age (a) of the soleus (b) and TA muscles (c) that were dissected out from WT and V mice at 6
and 8 weeks (n = 6) (**p < 0.01, ***p < 0.005). d Left panel shows dissected soleus muscles from wild-type (WT) (top row) and VDR−/− mice (V)
(bottom row) at 6 and 8 weeks of age. Right panel shows a representative western blot analysis of the lysates from the same subset of muscles
from WT and V and probed for p-Stat3 antibody (top panel) and total Stat3 (middle panel). Graphs to the right show quantitative analyses of
replicative blots of the ratio of relative intensities of p-Stat3 to total Stat3 at 6 and 8 weeks, respectively, between WT and V muscles (n = 6) (**p
< 0.01). e Left panel shows dissected tibialis anterior (TA) muscles from WT (top row) and V mice (bottom row) at 6 weeks and 2 months of age.
Right panel shows a representative western blot analysis of lysates from the same subset of muscles from WT and V and probed with antibodies
as in d. Graphs to the right show similar analyses as d of ratios of p-Stat3 to total Stat3 at 6 and 8 weeks, respectively, between WT and V muscles
(n = 6) (***p < 0.005). Total Stat3 levels were first normalized to β-actin that serves as a loading control prior to normalization of p-Stat3 to
total Stat3
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of age [31]. Hence, we chose time points spanning
through midlife to avoid secondary consequences from
external confounding factors that contribute to the
progressive nature of the abnormalities. While no differ-
ences in body weight could be observed at 2 weeks of age,
both the soleus and TA muscles from VDR−/− mice dis-
play reduced weight in comparison to age- and sex-
matched wild-type littermate controls examined at 6 weeks
and 2 months (Fig. 1b, c, respectively).
To test whether levels of p-Stat3 are elevated in VDR
−/− muscles, we isolated the soleus and TA muscles from
wild-type and VDR−/− mice that were 6 and 8 weeks old.
Western blot analysis revealed that p-Stat3 levels were
significantly increased in both the soleus and TA mus-
cles of VDR−/− mice compared to those of wild-type
mice at both ages examined, while comparable total
Stat-3 levels at each time point remained unchanged be-
tween WT and V muscles (Fig. 1d, e).
To investigate the consequence of p-Stat3 signaling on
muscle atrophy, we analyzed the expression of Myosta-
tin, a gene that has been demonstrated to be a key medi-
ator of atrophy and a target of Stat3 signaling [22], in 8-
week-old wild-type and VDR−/− mice. We found that
Myostatin expression levels were significantly increased
in both soleus and TA muscles from VDR−/− mice com-
pared to those of wild-type mice (Fig. 2a).
Further, to assess the consequences of increased Myos-
tatin function, we examined downstream p-Smad signal-
ing in muscles from VDR−/− mice. Myostatin binds to
receptor complexes, activin llb, and Alk4/Alk5 receptors
that leads to the phosphorylation, activation, and trans-
location of p-Smad transcription factors into the nucleus
[32, 33]. We found that both subsets of muscles in the
VDR−/− mice displayed elevated p-Smad3 signaling com-
pared to wild-type mice (Fig. 2b). Both in vitro and in
vivo experiments have shown that Myostatin signaling
inhibits the activation of the mTOR/p70 S6 kinase
(p70S6K) pathway, thereby promoting muscle atrophy in
various catabolic conditions [32, 34, 35]. To assess the
effects of vitamin D signaling on the mTOR pathway, we
analyzed the levels of phosphorylated p70S6K (p-
p70S6K) in VDR−/− muscles. We found that both the so-
leus and TA muscles of VDR−/− mice displayed reduced
levels of p-p70S6K in comparison to wild-type mice
(Fig. 2c, d). Of the many known substrates of p70S6K,
ribosomal protein S6 (rpS6) has been shown to be dir-
ectly involved, via its phosphorylation in regulating cell
size [24]. To examine the effects of p-Stat3 signaling on
muscle metabolic activity, we analyzed levels of phos-
phorylated rpS6 (p-rpS6) from the soleus and TA mus-
cles of 6-week-old VDR−/− mice (Fig. 1). Consistent with
reduced p70S6kinase activity, we observed a reduction
in p-rpS6 levels compared to wild-type mice of the same
age (Fig. 2e, f ).
In addition to Myostatin, skeletal muscle atrophy has
been demonstrated to be characterized by the expression
of markers such as FOXO3, muscle-specific E3 ubiquitin
ligase, muscle-RING finger 1 (MuRF1), which is known
to mediate the ubiquitin-proteasomal pathway, and C/
EBP δ, an effector of Stat3 signaling and a key mediator
of the transcriptional activity of Myostatin [22, 36, 37].
While C/EBP δ transcripts were observed to be upregu-
lated in both VDR−/− soleus and TA muscles, Foxo3 and
MuRF1 transcripts displayed a fiber-type-specific pattern
of expression, suggesting that slow and fast muscles
exhibit differences in the atrophic program induced in
the absence of vitamin D signaling (Fig. 2g, h).
Another highly conserved pathway that determines the
stability of proteins in the skeletal muscle is autophagic/
lysosomal pathway [27]. To evaluate the status of
autophagy in VDR−/− muscles, we assessed levels of
LC3b and Bnip3 in the soleus and TA muscles of these
mice. We found a significant decline in the expression of
both LC3b and Bnip3 in both subsets of VDR−/− muscles
compared to wild-type muscles, indicating a block in the
autophagic process (Fig. 2i, j).
IL-6 protein levels are increased in the soleus but not in
the TA muscles of VDR−/− mice
Several pro-inflammatory cytokines (IL-6, IFNγ, and
TNFα) are elevated in various catabolic conditions and
may trigger muscle wasting by increasing the expression
of NF-kB, promoting the expression of other cytokines,
or by modulating the activity of regulators of protein
synthesis [22, 38]. To investigate the role of cytokines in
promoting atrophy in the absence of vitamin D signal-
ing, we estimated the levels of IL-6, IFNγ, and TNFα in
the sera and muscle lysates of VDR−/− mice. We used
ELISA kits specific for mouse IL-6, IFNγ, and TNFα to
obtain standard curves for the respective cytokines
(Additional file 1: Figure S1A–C). We did not observe
any significant differences in the levels of these cytokines
in the sera of VDR−/− mice compared to wild-type mice
(Fig. 3a). However, in ELISA assays performed on
muscle lysates isolated from VDR−/− and wild-type mice,
we observed that IL-6 protein levels and not IFNγ, and
TNFα, from VDR−/− soleus muscles were significantly
higher than those compared to wild-type soleus muscles
(Fig. 3b). On the other hand, IL-6 protein levels were
not enhanced in the TA muscles of VDR−/− mice com-
pared to those of wild-type mice (Fig. 3c). Corroborating
these results, we found an increase in IL-6 protein levels
in the soleus muscles of VDR−/− mice using western blot
analysis (Fig. 3d). These results are consistent with the
reports on the preferential activation of Stat3 by IL-6
and the increase in IL-6 gene expression in slow muscles
during exercise [39–42] and suggest that elevated levels
of IL-6 protein could contribute to the increase in p-
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Fig. 2 VDR−/− muscles are characterized by an increase in atrophic gene expression, a decline in mTOR pathway components, and a
block in autophagic gene expression. a The soleus and TA muscles from 6-week-old WT and V mice were assessed for levels of Myostatin
transcript by qRT-PCR. Myostatin transcript levels in the soleus and TA muscles of V mice are normalized to those in WT (n = 6) (*p < 0.05).
Myostatin is upregulated in the soleus and TA muscles of V compared to WT. b Graph showing the quantitation of western blot analysis
of lysates from dissected soleus muscles (Fig. 1b) and TA muscles (Fig. 1c) from WT and V mice at 6 weeks of age probed for p-Smad3
antibody (n = 5) (**p < 0.01, ***p < 0.005). GAPDH serves as a loading control. c–f Representative western blot analysis of lysates from
dissected soleus muscles (Fig. 1b) and TA muscles (Fig. 1c) from WT and V mice at 6 weeks of age probed for p-p70S6K antibody and
S6K antibody (c, d) and p-rpS6 antibody and total rpS6 (e, f). Graphs below each blot show ratios of p-p70S6K to total S6K and p-rpS6 to
total rpS6, respectively (n = 5) (**p < 0.01, ***p < 0.005). GAPDH serves as a loading control. g, h Soleus and TA muscles from 6-week-old
WT and TA muscles were assessed for known markers of atrophy, Foxo3, Murf1, and C/EBP δ transcripts by qRT-PCR. While C/EBP δ was
upregulated in both muscles sets, Foxo3 and Murf1 showed differential fiber-type-specific expression (n = 5) (**p < 0.01, ***p < 0.005). i–j
Soleus and TA muscles from 6-week-old WT and TA muscles were assessed for known markers of autophagy, LC3b and Bnip3 transcripts,
by qRT-PCR. Both transcripts were downregulated in V muscles compared to WT muscles. All transcript levels in V are normalized to those
in WT (n = 5) (**p < 0.01, ***p < 0.005)
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Stat3 signaling in the soleus, while presumably other up-
stream factors promote increase p-Stat3 in the TA mus-
cles of VDR−/− mice.
VDR−/− SCs are similar to wild-type SCs in numbers and
Myostatin expression but display hallmarks of atrophy
upon differentiation in culture
To investigate the effects of VDR-deficient status on the
SC compartment in skeletal muscles, we isolated SCs by
FACS as previously described [29] from the hind limb
muscles of VDR−/− mice and wild-type mice (Fig. 4a).
We did not observe any differences in the relative pro-
portion of SCs in bulk muscles isolated from wild-type
mice and VDR−/− mice (Fig. 4a, third panel in the top
and bottom rows, respectively). We then isolated single
muscle fibers from wild-type and VDR−/− muscles and
fixed them immediately after isolation. We stained fibers
with a Pax7 antibody that identifies quiescent SCs and
found no significant differences in SC numbers between
wild-type and VDR−/− fibers, consistent with the FACS
results (Fig. 4b). These results suggest that VDR signal-
ing does not influence specification and maintenance of
SC numbers and that the muscle atrophy observed in
VDR−/− mice is not due to a deficit in SC numbers in
these muscles.
Since expression levels of Myostatin were found to be
significantly upregulated in both muscle sets in the VDR
−/− mice and Myostatin is a key regulator of self-renewal
in SCs, we wanted to investigate whether changes in
Myostatin expression in VDR−/− SCs accompany atrophy
in VDR−/− muscles. Unlike in the fibers, quantitative RT-
PCR analysis revealed no significant differences in levels
of Myostatin expression between VDR−/− and wild-type
SCs (Fig. 4c). This suggests that a role for Myostatin in
promoting atrophy in VDR−/− muscles is predominantly
confined to the regulation of its expression within fibers
rather than the SC compartment.
Since the molecular changes described thus far were
observed in a global knockout of VDR, raising the possi-
bility of our observations emerging as secondary conse-
quences to metabolic perturbations in the muscle niche,
we cultured FACS-isolated SCs in vitro and differenti-
ated them for 2 days to obtain an independent validation
of our results (Fig. 4d). We observed that SC progeny
from both VDR−/− and wild-type muscles displayed
Myogenin expression upon differentiation in culture
(Fig. 4d). A western blot analysis on cell lysates from
VDR−/− myotubes revealed elevated levels of p-Stat3
compared to wild-type myotubes (Fig. 4e). Further, qRT-
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Fig. 3 VDR−/− soleus but not TA muscles display increased IL-6 protein levels. a Serum IL-6, IFNγ, and TNFα levels were measured by ELISA in
triplicate wells from 8-week-old WT and V mice. Graph shows that no significant differences in cytokine levels were observed in the serum from
the two sets (n = 5). b, c Cytokine levels in a were measured in the soleus (b) and TA (c) muscle lysates isolated from 8-week-old WT and V mice.
Only IL-6 levels were observed to be significantly increased in the soleus muscles of V mice (n = 5) (**p < 0.01). Cytokine levels were normalized
to tissue weight (mgs). d Top and bottom panels show a representative western blot analysis of lysates from the soleus and TA muscles,
respectively, of WT and V mice probed with IL-6 antibody. Graph to the right shows the quantitative differences between the two groups. IL-6
protein levels are increased in the soleus but not in the TA muscles of V compared to WT mice. GAPDH serves as the loading control (n = 6)



















































































































































Fig. 4 VDR−/− SCs do not differ in number or Myostatin expression from wild-type SCs but display hallmarks of atrophy upon differentiation in
culture. a SC numbers were quantified by FACS analysis of mononuclear cells from hind limb muscles of WT and V mice. SCs are shown in purple
(WT) and blue (V) in these representative FACS plots. In three replicates, the percentage of SCs in total mononuclear cells in V muscles was not
significantly different (1.5%) compared to that in WT muscles (1.7%) (n = 3 mice per genotype were pooled per experiment, N = 3). b
Single myofibers were obtained from WT and V muscles and stained for Pax7 to assess SC numbers per fiber. There were no statistically
significant differences in the number of SCs per fiber between the two strains. Fibers were obtained from three mice per genotype. c
FACS-purified quiescent SCs from WT and V mice muscles were assessed for levels of Myostatin expression by qRT-PCR. Myostatin
transcript levels in V are normalized to WT. Quiescent SCs from each genotype represent triplicate experiments of pooled RNA from
three mice for each experiment (n = 3 mice per genotype were pooled per experiment, N = 3). d FACS-sorted SCs from WT and V hind
limb muscles were induced to differentiate for 2 days and stained for Myogenin. e Western blot analysis of lysates from differentiated
SC cultures from WT (WT MT) and V (V MT) mice were probed with p-Stat3 and total Stat3 antibodies. Graph below shows a significant
upregulation in p-Stat3 levels in V MT cultures compared to those in WT MT (n = 3 mice per genotype were pooled per experiment, N
= 3). (**p < 0.01). f Myotubes from WT and V muscles were assessed for levels Myostatin expression by qRT-PCR. Myostatin is upregulated
in V myotubes compared to WT myotubes (*p < 0.05)
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significantly elevated Myostatin expression compared to
wild-type myotubes (Fig. 4f ). Taken together, these
results suggest an intrinsic deficit in the SC compart-
ment that could impair their ability to contribute to
postnatal muscle growth in the absence of vitamin D
signaling.
Inhibition of Stat3 signaling ameliorates muscle mass loss
in slow but not fast muscles of VDR−/− mice
To determine whether a pharmacological inhibition of
Stat3 signaling can be used to block muscle wasting
observed in the VDR−/− mice, we injected four-and-a-
half-week-old VDR−/− mice that had been paired for
their body weights or wild-type mice with C188-9, a
small molecule inhibitor of Stat3 or the diluent, with
5DW for 2 weeks. We found that C188-9-treated VDR
−/− mice displayed a significant increase in the wet
weight of soleus (45% over vehicle-treated VDR−/−
mice), but not the TA muscles after treatment, al-
though there were no significant changes in the total
body weight of the mice (Fig. 5a). However, the soleus
muscles from wild-type mice injected with C188-9 did
not show any differences in muscle weight from the
vehicle-treated controls (Fig. 5a). Further analysis re-
vealed that while C188-9 treatment did not decrease
the level of p-Stat3 in wild-type soleus and TA mus-
cles (Additional file 2: Figure S2A), VDR−/− mice
injected with C188-9 displayed a significant reduction
in p-Stat3 levels in the soleus (Fig. 5b (i), top and bot-
tom panels, and Fig. 5b (iii)) but not in the TA mus-
cles (Fig. 5b (ii), top and bottom panels, and Fig. 5b
(iii)). To investigate the status of Stat3 signaling in
other muscles in inhibitor-treated animals, we isolated
the quadriceps muscle, which like the TA has a pre-
dominance of type ll fibers, and found that while there
was an increase in p-Stat3 levels in VDR−/− quadriceps
compared to the wild-type, C188-9 treatment did not
ameliorate muscle mass loss or decrease the level of p-
Stat3 in quadriceps muscles compared to vehicle-
injected control VDR−/− mice (Additional file 3: Figure
S3A–C). To evaluate the consequences of amelior-
ation of the atrophic response due to decreased p-
Stat3 levels on changes in gene expression, we
assessed levels of Myostatin in the soleus and TA mus-
cles of C188-9-treated and vehicle-treated VDR−/− and
wild-type mice. We found that there was a significant
decrease in Myostatin expression in the soleus muscles
of C188-9 treated VDR−/− mice and not in the TA
muscles compared to vehicle-injected controls, con-
sistent with an amelioration of atrophy in the soleus
muscles (Fig. 5c). Similarly, C/EBP δ and Foxo3 ex-
pressions that were previously found to be upregulated
in the soleus muscles of VDR−/− mice also declined
upon inhibitor treatment (Fig. 5d). However, wild-type
mice injected with C188-9 did not show any relative
differences in Myostatin expression from vehicle-
injected controls (Fig. 5c). These results suggest that
compared to slow muscles, the fast muscles are less
responsive to the inhibition of Stat3 signaling.
To examine the consequences of Stat3 pharmaco-
logical inhibition on gross morphometry of the soleus
muscles, we stained cryosections of the soleus muscles
isolated from these mice with hematoxylin and eosin
(Fig. 5f, left and right panels for control and treated
VDR−/− mice, respectively). While we observed a wide
variation in the size of fibers in VDR−/− mice consistent
with earlier observations [13], VDR−/− mice injected with
C188-9 displayed a reduced number of smaller fibers
(100–200 μm) compared to vehicle-injected controls
(Fig. 5e). Additionally, we observed a greater homogen-
eity in the larger fibers (300–400 μm) in VDR−/− mice
injected with C188-9 (S.D ± 1.414, n = 5 mice in three in-
dependent experiments), compared to vehicle-injected
controls (S.D ± 5.2, n = 5 in three independent experi-
ments), and a significant increase in fibers with sizes
from 400 to 500 μm (Fig. 5e).
Amelioration of muscle mass in the soleus of VDR−/− mice
is accompanied by a decline in Myostatin function and
restoration of mTOR signaling
Since we observed an amelioration of muscle mass in
soleus muscles and a decline in Myostatin expression
in inhibitor-treated VDR−/− mice, we examined down-
stream p-Smad signaling as a consequence of de-
creased Myostatin function. We found that VDR−/−
mice injected with C188-9 displayed a significant re-
duction in p-Smad3 levels in the soleus, but not in the
TA muscles (Fig. 6a (i–iii)). As a representative ex-
ample to confirm the identity of the lanes, we also
probed these blots with an anti-Myosin heavy chain
(HC) antibody specific to slow muscles. Interestingly,
we found that VDR−/− soleus muscles displayed
reduced levels of slow Myosin HC compared to those
of the wild-type, suggesting that there could be a
decline in sarcomere integrity in the absence of VDR
signaling (Fig. 6a (i)).
To further evaluate the consequences of p-Stat3 inhib-
ition and reduced Myostatin signaling on the mTOR/
p70S6K pathway, we examined the status of p-p70S6k
and its downstream effector, p-rpS6 (Fig. 6b, c). We
found that p-p70S6K levels increased in VDR−/− mice
injected with C188-9 in the soleus but not in the TA
muscles (Fig. 6b (i–iii)). Similarly, p-rpS6 levels were also
restored in the soleus muscles of inhibitor-treated VDR
−/− mice, an effect that was not observed in the VDR−/−
TA muscles or in the wild-type mice injected with C188-
9 (Fig. 6c (i–iii) and Additional file 2: Figure S2B).
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Fig. 5 Inhibition of Stat3 activity ameliorates muscle mass loss in VDR−/− soleus muscles. a Average weights of the soleus (left graph) and TA
muscles (right graph) from WT and paired V mice that were injected with either the diluent (WT and V, respectively) or C188-9 (WT + I and V + I,
respectively) after 2 weeks of treatment (n = 5 mice/group, N = 3 independent experiments). Soleus muscles from V + I mice show a significant
increase in weight compared to those from V mice injected with diluent (*p < 0.05). b (i) and (ii) Representative western blot analysis of lysates in
duplicate from independent experiments from soleus (i), top and bottom left panels, and TA muscles (ii), top and bottom right panels, from WT, V,
and V + I mice. Blots were probed with p-Stat3 antibody. Fold differences in p-Stat3 levels were calculated by normalizing intensities with
respective GAPDH values (n = 5 mice/group, N = 3 independent experiments). (iii) Graph shows quantitative analyses of replicative blots of levels
of p-Stat3 protein in the TA and soleus muscles after inhibitor treatment (**p < 0.01, ***p < 0.005). A detectable decrease in p-Stat3 levels were
observed in soleuses of V + I mice, but not in the TA muscles. c The soleus muscles (left graph) and TA muscles (right graph) from paired V and V
+ I mice and WT + I mice and were assessed for Myostatin transcript levels by qRT-PCR. There was a significant decline in Myostatin expression in
V + I soleus muscles compared to control V muscles, but not in the TA subset of inhibitor-treated V mice (*p < 0.05). d The soleus muscles from
same group as c were assessed for C/EBP δ and Foxo3 expression by qRT-PCR. There was a reduction in C/EBP δ and Foxo3 expression in V + I
soleus muscles compared to control V muscles (**p < 0.01, ***p < 0.005). e–f Cryosections of the soleus muscles isolated from V (top panel) and V
+ I (bottom panel) mice were stained for hematoxylin and eosin. Individual fibers were evaluated for cross-sectional area (CSA) in both groups. A
minimum of 800 fibers were counted per section from soleuses in three independent experiments for each genotype. V + I soleus fibers show
reduced number of smaller fibers of sizes 100–200 μm and a greater homogeneity in fibers with sizes 300–400 μm (S.D = 1.414 for V + I compared
to 5.2 for V) (*p < 0.05). There was also a significant increase in fibers with sizes from 400 to 500 μm. Scale bars represent 100 μm
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Differential response of fiber types to Stat3
pharmacological inhibition could be due to preferential
fiber type p-Stat5 levels and its dependence on vitamin D
signaling
To address our observations on the differential responses
of the soleus and the TA muscles to Stat3 pharmacological
inhibition, we hypothesized (a) the presence of a key regu-
lator that displays preferential fiber-type-specific function
and (b) whose absence results in quantitatively higher
levels of p-Stat3 relative to the other subset of muscles,
thereby rendering the pharmacological intervention inef-
fective. Previous studies have shown that in the skeletal
muscle, Stat5 functions to repress Stat3 expression, such
that a muscle-specific knockout of Stat5 results in the
upregulation of Stat3 mRNA [43]. To check the expres-
sion and activity of Stat5 in slow versus fast muscles, we
performed a western blot analysis of lysates isolated from
wild-type soleus and TA muscles. We found that p-Stat5
was expressed at significantly higher levels in the TA than
in the soleus muscles (Fig. 7a). A similar observation was
made between muscle subsets isolated from VDR−/− mice
(Fig. 7a). Importantly, we found that p-Stat5 levels were
downregulated in a quantitative comparison between the
TA muscles of VDR−/− and wild-type mice, indicating that
VDR signaling promotes Stat5 function (Fig. 7a).
To address the possibility that reduced levels of p-
Stat5 because of absent VDR signaling might account
for the higher levels of p-Stat3 in the TA muscles rather
than in the soleus muscles of VDR−/− mice, we com-
pared active and total Stat3 levels in the TA and soleus
muscles of VDR−/− mice (Fig. 7b). We observed quanti-
tatively higher levels of not only p-Stat3 but also total
Stat3 levels in the TA muscles of VDR−/− mice compared
to those in the soleus muscles (Fig. 7b). Thus, Stat5 ac-
tivity imposes an additional level of regulation on the
Stat3-Myostatin axis in fast muscles, such that upon its
downregulation during reduced vitamin D signaling, p-
Stat3 levels increase several folds in fast muscles com-
pared to slow muscles, thereby impeding effective
pharmacological inhibition.
Taken together, our results suggest a working model
whereby vitamin D maintains muscle mass by inhibiting
Stat3 signaling and Myostatin expression and function,
thereby sustaining mTOR signaling and promoting
protein synthesis. In fast muscles, vitamin D promotes
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Fig. 6 Inhibition of Stat3 activity ameliorates the changes in levels of mTOR components observed in VDR−/− soleus muscles. a–c (i) and (ii)
Representative western blot analysis of lysates from b were probed with p-Smad3 (a), p-p70S6K (b), and p-rpS6 (c) antibodies. The p-Smad3 blot
was also probed with MHC (slow) as a representative example to mark the identity of the lanes. a–c, (iii) Graphs show fold differences in
p-Smad3, p-p70S6K, and p-rpS6, respectively, that were calculated by normalizing intensities with respective GAPDH values (n = 5 mice/group,
N = 3 independent experiments) (*p < 0.05, **p < 0.01). While p-Smad3 levels were reduced in the soleus muscles of inhibitor-treated V mice,
p-p70S6K and p-rpS6 levels were increased
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slow muscles, vitamin D reduces IL-6 cytokine levels as
a mechanism to suppress Stat3 signaling (Fig. 8).
Discussion
Our results demonstrate that VDR−/− muscles display
elevated Stat3 signaling and increased Myostatin expres-
sion. Increased Myostatin signaling induces p-Smad3
activity that is known to suppress mTOR signaling. Con-
sequently, we observed a decline in p-p70S6K and p-
rpS6 levels in VDR−/− muscles. More importantly,
pharmacological inhibition of Stat3 function decreased
p-Stat3, Myostatin expression, and p-Smad3 levels, while
restoring p-p70S6K and p-rpS6 levels resulting in an
amelioration of muscle mass loss, an effect that was
observed in the soleus muscles of VDR−/− mice.
Inhibition of Stat3 function ameliorates the loss of muscle
mass in slow muscles
Although fiber type sensitivities to atrophy vary depend-
ing on the atrophic stimuli, VDR−/− muscles have been
reported to display smaller fiber diameter, irrespective of
the fiber type [13, 44]. In keeping with this observation,
p-Stat3 signaling was found to be elevated in both fast
(TA and quadriceps) and slow (soleus) muscles of VDR
−/− mice suggesting a common contributory factor for
promoting the atrophic process in both fiber types.
However, we observed that the soleus and not the TA or
quadriceps muscles responded to the inhibition of Stat3
function. Our results confirmed the hypothesis that the
relative levels of p-Stat3 in VDR−/− fast muscles could be
higher than those in the soleus muscles, resulting in the
wasting process being more effectively blocked by the
pharmacological inhibitor in the soleus muscles alone
(Fig. 7b). Since Stat3 plays a crucial role in cell prolifera-
tion and motility during early development and SCs are
rapidly dividing until 3 weeks after birth to contribute to
myofiber growth, we chose to initiate the inhibition of
Stat3 function after this critical period to avoid interfer-
ing with myogenic activity during early postnatal devel-
opment [45, 46]. Additionally, the dose and extent of
treatment was the same as that used in a previous study
to inhibit loss of muscle mass observed in models of
muscle wasting in mice [22]. This was done to ensure ef-
fective inhibition of Stat3 function without confounding
effects, thus making it unlikely that the observations
made in this study were restricted to the format of the
treatment regimen alone. Our results propose a working
model wherein high levels of p-Stat3 in VDR−/− fast
muscles could very likely be the result of dysregulated
expression of Stat5 in the absence of VDR signaling
(Fig. 7a). Corroborating this evidence, Stat5 has been
demonstrated to be induced after treatment with 1α,25-
dihydroxyvitamin D3 in osteoclast cells [47]. Thus, in
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Fig. 7 Different levels of Stat3 expression and activity in VDR−/− muscle subsets amenable to pharmacological inhibition could be linked to
preferential fiber type expression of p-Stat5 and its dependence on vitamin D signaling. a Representative western blot analysis of lysates from the
soleus and TA muscles isolated from 6-week-old WT and V mice were probed with p-Stat5 and total Stat5 antibodies. Graph below show the fold
differences in levels of p-Stat5 to total Stat5 protein that was calculated after normalizing band intensities with respective GAPDH values (n = 5
mice/group, ***p < 0.005). Levels of p-Stat5 are significantly higher in the TA muscles than those in the soleus muscles and are downregulated in
the absence of VDR signaling. b Western blot analysis of lysates from the soleus and TA muscles of V mice were probed with p-Stat3 and total
Stat3 antibodies. Graph below shows the fold differences in levels of p-Stat3 and total Stat3 after normalizing band intensities with respective
GAPDH values (n = 5, ***p < 0.005, **p < 0.01). Blots were probed with MHC (slow) to mark the identity of the lanes. The TA muscles express
significantly higher levels of p-Stat3 and total Stat3 compared to the soleus muscles from V mice
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increase due to a reduction in Stat5 function. Addition-
ally, Stat5 functions to repress genes associated with type
1 fibers, a report that is consistent with our finding that
Stat5 function is quantitatively lower in type 1 fibers
(Fig. 7a) [43]. Together, these results suggest that the
Stat5-Stat3 regulatory axis is critical in type II fibers,
serving to suppress the expression of genes associated
with slow fibers and posing as an additional level of
regulation of p-Stat3 activity in fast fibers. As such, a
combinatorial treatment ensuring increased Stat5 func-
tion and decreased Stat3 signaling might contribute to
increased weights in muscles with type ll fiber predom-
inance in vitamin D-lacking muscles. Another implica-
tion of the intriguing observation that p-Stat3 inhibition
ameliorated muscle mass only in the soleus (Fig. 5)
suggests the possibility of additional mechanisms that
function to restrict p-Stat3 signaling in fast muscles. The
downregulation of these modulators that are (a) fast
fiber type specific, (b) dependent on vitamin D signaling,
and (c) that impinge on the Stat3-Myostatin axis could
render fast muscles more susceptible to atrophy than
slow muscles, a phenomenon that is observed in vitamin
D deficiencies in humans [20]. In this study, we suggest
that p-Stat5 signaling could be one such modulator that
contributes to the fiber-type-specific effects of vitamin D
signaling in wild-type muscles, such that fast muscles
that display relatively higher levels of p-Stat5 signaling
are more responsive to the growth-promoting effects of
vitamin D function. Conversely, slow muscles would be
susceptible to a lesser extent to modulations in p-Stat5
activity as a consequence of altered vitamin D signaling.
Thus, despite displaying generalized fiber atrophy, the
VDR−/− mouse model might offer insights into identify-
ing mechanisms that promote fiber-type-specific atrophy
during vitamin D deficiency.
Key regulators of muscle mass are altered in the absence
of vitamin D signaling
Studies examining the effects of vitamin D on myotube
formation in C2C12 cell cultures have revealed an
increase in myotube size following treatment with
1α,25(OH)2D3 in a manner independent of its effects on
myoblast differentiation [48, 49]. Our results corroborate



































Fig. 8 Working model representing the proposed signaling pathways induced by vitamin D signaling in regulating skeletal muscle mass.
Active vitamin D bound to vitamin D receptors maintains proteostasis by inhibiting p-Stat3 signaling and downstream C/EBP δ activity,
thereby inhibiting the production of Myostatin. In fast muscles, active vitamin D additionally promotes p-Stat5 expression that could
function to inhibit Stat3 expression and function. In the absence of vitamin D signaling, increased levels of Myostatin induces p-Smad3
signaling, which in turn inhibits components of the mTOR pathway, p-p70S6 kinase, and p-rpS6. Translocation of active FOXO3 into the
nucleus due to reduced mTOR pathway signaling can upregulate the expression of various atrogenes. Paradoxically, autophagy regulators
and targets of FOXO3 signaling, LC3b and Bnip3, display decreased expression, suggesting a block in the autophagic process and possibly
an inhibition of recruitment of FOXO3 to the promoters of these genes. Additionally, active vitamin D reduces IL-6 production in slow
muscles, possibly through the inhibition of the NF-kb complex that further attenuates p-Stat3 signaling
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signaling, key regulators of cell size and tissue mass such
as Myostatin, p70S6K, and p-rpS6 are altered. Several
possible mechanisms offer clues as to how p-Stat3 might
induce muscle wasting in VDR−/− mice. Firstly, VDR−/−
muscles in response to elevated Stat3 signaling display a
reduction in p-rpS6 levels (Fig. 2), a key regulator of cell
growth which upon inhibition mirrors suppression of
mTOR function in the regulation of cell size [24, 50]. A
similar pattern of molecular expression has been re-
ported in a recent study to characterize muscle atrophy
following burn injuries, wherein human skeletal muscle
SCs incubated in burn serum displayed elevated Stat3
levels and decreased p70S6K and p-rpS6 protein levels
[51]. In rpS6P−/− mice, it was shown that although mouse
embryonic fibroblasts (MEFs) derived from these mice
were significantly smaller than rpS6P+/+ MEFs, there was
no corresponding decline in global protein synthesis, sug-
gesting that the atrophy observed in VDR−/− mice cannot
be explained solely by a decline in protein synthesis [24].
Whether other cellular components are affected by de-
creased rpS6 activity have yet to be investigated. In relation
to the role of rpS6 in skeletal muscles, it has been demon-
strated that the soleus muscles from the rpS6P−/− mice dis-
played a decrease in muscle mass due to a diminished
abundance of contractile proteins and reduced energy con-
tent, thereby supporting the function of rpS6 as a potential
mediator of the effects of vitamin D signaling on muscle
mass [52]. Of the contractile proteins downregulated in
rpS6P−/− soleus muscles, Myosin HC was also observed to
be reduced in VDR−/− soleus muscles, further corroborat-
ing the role of rpS6 downstream of VDR signaling [52]
(Figs. 6 and 7). Secondly, we observed a significant upregu-
lation of Myostatin expression, a potent negative regulator
of muscle mass in the VDR−/− mice, in sets of muscles that
differ in their fiber type content (Fig. 2a). Increased levels
of Myostatin have been found in aging subjects and in
various diseases that are characterized by muscle wasting
[53]. It has been demonstrated that p-Stat3 elevates Myos-
tatin expression through the modulation of CCAAT/en-
hancer-binding protein (CEBP) δ and that the Myostatin
promoter bears multiple binding sites for CEBP δ [22]. In-
deed, in our studies, we observed an upregulation in CEBP
δ transcript levels in both the soleus and TA muscles of
VDR−/− mice (Fig. 2g–h). Additionally, treatment of
C2C12 myoblasts with 1α,25(OH)2D3 downregulated
Myostatin expression, suggesting a causal link between
vitamin D signaling and a key regulator of muscle mass
[48]. Moreover, we also see an upregulation in Foxo3 ex-
pression, which is known to cause a dramatic atrophy in
myotubes and muscle fibers through its effects on autoph-
agy, such that a knockdown of LC3, a protein involved in
autophagosome formation, partially ameliorates Foxo3-
mediated muscle mass loss (Fig. 2g) [27]. However, the
upregulation of Foxo3 expression was more apparent in
the soleus muscles rather than in the TA muscles of the
VDR−/− mice, an observation that stands in contrast to
the study on Foxo3 in mediating glycolytic (type 2) rather
than in oxidative (type 1) fiber atrophy [54]. These results
might be more explained by the stimuli that initiate the at-
rophy process in various muscle wasting models. For ex-
ample, VDR−/− mice are known to display impaired motor
functions and type 1 fiber atrophy is more sensitive to
neuromuscular perturbations [31, 55]. As such, the upreg-
ulation of Foxo3 mRNA in the soleus might be the
outcome of a combination of metabolic and neural abnor-
malities. Surprisingly, an analysis of the expression pattern
of key autophagic genes, LC3b and Bnip3, that mediate
the effects of Foxo3 on autophagy was found to be down-
regulated in VDR−/− muscles, suggesting a block in the au-
tophagic process (Fig. 2i–j). This could lead to the
accumulation of damaged and dysfunctional organelles
that impair tissue function, as observed in the Atg7−/−
mice that lack the unique E1 enzyme of the autophagic
machinery [56]. The block in autophagy causes disorga-
nized sarcomeres, myofiber degeneration, and accumula-
tion of polyubiquitinated proteins that manifest in the
form of severe muscle weakness and myopathy in the
Atg7−/− mice [56]. However, detailed molecular analyses
such as the visualization of LC3-positive granules and p62
protein that recruits autophagic vesicles to ubiquitylated
mitochondrial proteins as well as mitochondrial network
remodeling are critical in distinguishing between a stalled
autophagic process and increased turnover rates of au-
tophagic markers that prevent their detection. Neverthe-
less, our initial results are indicative of a dysfunctional
autophagic process in VDR−/− muscles that could exacer-
bate muscle wasting.
Effects of the absence of vitamin D signaling on SC
numbers and Myostatin expression
Several recent reports have addressed the molecular
changes taking place in the stem cell compartment
accompanying various forms of atrophy [57]. Studies
examining the changes in SC compartment in muscle
wasting conditions such as aging and hind limb suspen-
sion have reported variable results from a reduction to
no differences in SC numbers under these conditions
[58–60]. In our study, we observed that VDR−/− muscles
do not possess a stem cell deficit compared to wild-type
muscles, underscoring the need for a qualitative assess-
ment of SC functionality, rather than quantitative
parameters (Fig. 4a, b). These results indicate that
vitamin D signaling does not play a decisive role in de-
termining the numbers of SCs during development. We
also observed that Myostatin mRNA levels were
unaltered in quiescent VDR−/− muscles, unlike their
expression in fibers, indicating a differential regulation
in fiber and SC compartments within the atrophying
Gopinath Skeletal Muscle  (2017) 7:2 Page 14 of 17
VDR−/− muscles (Fig. 4c). Indeed, Myostatin mRNA
levels were reported to be unaltered in human muscle
precursor cells upon 1α,25(OH)2D3 treatment [14], sug-
gesting that the modulation of Myostatin in VDR−/−
muscles might be confined to the fiber alone.
Conclusions
The purpose of our study was to determine the molecu-
lar mechanisms underlying the loss of skeletal muscle
mass in the absence of vitamin D signaling. In the ab-
sence of vitamin D signaling, both the soleus and the TA
muscles that represent examples of slow and fast subsets
of muscles, respectively, display an increase in p-Stat3
levels and Myostatin expression. Consequently, p-Smad3
signaling is induced that suppresses p-p70S6K and p-
rpS6 levels. In addition to Myostatin, we also observed
an increase in other atrogenes and a block in autophagy
in VDR−/− muscles. Investigations into the upstream
regulation of p-Stat3 revealed that IL-6 protein expres-
sion, albeit unaltered in the sera, was increased in the
soleus but not in the TA muscles in the absence of vita-
min D signaling. To understand the role of SCs in the
atrophy accompanying the absence of VDR signaling, we
found that SC numbers in VDR−/− mice muscles were
no different from wild-type, suggesting that active vita-
min D signaling is not a prerequisite for determining SC
numbers in the skeletal muscle. However, SC progeny
that were induced to differentiate in culture displayed an
increase in p-Stat3 levels and Myostatin expression indi-
cative of a cell-autonomous defect that could impair
their ability to participate in postnatal muscle growth or
regeneration. Concomitant to the inhibition of p-Stat3,
Myostatin-mediated suppression of mTOR signaling was
alleviated as evidenced by a restoration in the levels of
p-p70S6K and p-rpS6 activity in slow muscles. However,
the dysregulated function of Stat5 in the absence of
VDR signaling could be responsible for increasingly
higher levels of Stat3 expression and function, thereby
impeding effective pharmacological inhibition in fast
muscles.
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